Opiant Pharmaceuticals (OPNT) Reaches New 1-Year Low at $19.60
Opiant Pharmaceuticals Inc (NASDAQ:OPNT)’s share price reached a new 52-week low on Monday . The company traded as low as $19.60 and last traded at $22.55, with a volume of 72500 shares. The stock had previously closed at $23.50.
OPNT has been the subject of a number of analyst reports. TheStreet raised Opiant Pharmaceuticals from a “c+” rating to a “b” rating in a report on Monday, October 16th. ValuEngine cut Opiant Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, October 2nd.
The company has a market capitalization of $39.39, a price-to-earnings ratio of 53.69 and a beta of -0.28.
In other Opiant Pharmaceuticals news, major shareholder Geoffrey Wolf sold 2,570 shares of the stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $30.40, for a total transaction of $78,128.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 63.82% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Opiant Pharmaceuticals (OPNT) Reaches New 1-Year Low at $19.60” was posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/opiant-pharmaceuticals-opnt-reaches-new-1-year-low-at-19-60/1773760.html.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.